Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.

ABSTRACT:

Background

Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis.

Aim

To report efficacy and infection rates in patients receiving tofacitinib induction treatment, by baseline corticosteroid status.

Methods

We evaluated efficacy and safety data from OCTAVE Induction 1&2 in patients with moderately-to-severely active ulcerative colitis who received tofacitinib 10 mg twice daily or placebo for 8 weeks, based on induction baseline oral corticosteroid use (Corticosteroid-Yes/No) and dose (< 20/ ≥ 20 mg/day). Infections of interest included serious infections, herpes zoster (HZ), and adjudicated opportunistic infections (OIs).

Results

At OCTAVE Induction 1&2 baseline, 478/1092 (43.8%) patients were receiving corticoster

SUBMITTER: Lichtenstein GR 

PROVIDER: S-EPMC9899108 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature